China Healthcare Stocks On Recovery Path After $142 Billion Rout

China’s Junshi Nabs FDA Approval in Rare Success for US Foray

Merck Discontinues Developing Drug Candidates With Sichuan Kelun After Daiichi Sankyo Deal